JP2014509662A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509662A5
JP2014509662A5 JP2014502901A JP2014502901A JP2014509662A5 JP 2014509662 A5 JP2014509662 A5 JP 2014509662A5 JP 2014502901 A JP2014502901 A JP 2014502901A JP 2014502901 A JP2014502901 A JP 2014502901A JP 2014509662 A5 JP2014509662 A5 JP 2014509662A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
monoclonal antibody
use according
skin inflammation
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014502901A
Other languages
English (en)
Japanese (ja)
Other versions
JP6062918B2 (ja
JP2014509662A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031803 external-priority patent/WO2012135812A2/en
Publication of JP2014509662A publication Critical patent/JP2014509662A/ja
Publication of JP2014509662A5 publication Critical patent/JP2014509662A5/ja
Application granted granted Critical
Publication of JP6062918B2 publication Critical patent/JP6062918B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014502901A 2011-04-01 2012-04-02 皮膚科的病理の治療 Expired - Fee Related JP6062918B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470538P 2011-04-01 2011-04-01
US61/470,538 2011-04-01
PCT/US2012/031803 WO2012135812A2 (en) 2011-04-01 2012-04-02 Treatment for dermatological pathologies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016145710A Division JP6453278B2 (ja) 2011-04-01 2016-07-25 皮膚科的病理の治療

Publications (3)

Publication Number Publication Date
JP2014509662A JP2014509662A (ja) 2014-04-21
JP2014509662A5 true JP2014509662A5 (https=) 2015-05-21
JP6062918B2 JP6062918B2 (ja) 2017-01-18

Family

ID=46927554

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014502901A Expired - Fee Related JP6062918B2 (ja) 2011-04-01 2012-04-02 皮膚科的病理の治療
JP2016145710A Expired - Fee Related JP6453278B2 (ja) 2011-04-01 2016-07-25 皮膚科的病理の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016145710A Expired - Fee Related JP6453278B2 (ja) 2011-04-01 2016-07-25 皮膚科的病理の治療

Country Status (11)

Country Link
US (2) US20120251548A1 (https=)
EP (2) EP3417879A1 (https=)
JP (2) JP6062918B2 (https=)
KR (3) KR102326482B1 (https=)
CN (2) CN110201157A (https=)
AU (2) AU2012236106B2 (https=)
CA (1) CA2831126C (https=)
DK (1) DK2694107T3 (https=)
ES (1) ES2697056T3 (https=)
PT (1) PT2694107T (https=)
WO (1) WO2012135812A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6062918B2 (ja) * 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2013327498B2 (en) * 2012-10-04 2018-06-28 Janssen Biotech, Inc. Treatment of psychiatric conditions
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
US20230235042A1 (en) * 2020-04-16 2023-07-27 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
CA2147151A1 (en) 1992-10-14 1994-04-28 Robert A. Snow Therapeutic and diagnostic imaging compositions and methods
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5945576A (en) * 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
JPWO2002033094A1 (ja) 2000-10-19 2004-10-21 協和醗酵工業株式会社 Vplfの活性を阻害する抗体
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Amf類を有効成分とする医薬製剤
WO2006001967A2 (en) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
JP5866130B2 (ja) * 2010-09-10 2016-02-17 アペクシジェン, インコーポレイテッド 抗IL−1β抗体およびその使用方法
JP6062918B2 (ja) * 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Similar Documents

Publication Publication Date Title
JP2014509662A5 (https=)
JP2015531396A5 (https=)
CY2023005I1 (el) Διειδικα αντισωματα anti-vegf/anti-ang-2 και η χρηση τους στην αγωγη οφθαλμικων αγγειακων νοσων
NZ719368A (en) Combination therapy of antibodies against human csf-1r and uses thereof
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
HK1200714A1 (en) Fgfr-binder-active agent conjugates
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
BR112013002167A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EA201401204A1 (ru) Антитела к il-23p19
NZ630363A (en) Anti-kit antibodies and uses thereof
IL236892B (en) A combination of an immunoconjugate and an antibody for use in medical treatment, a pharmaceutical preparation and a kit containing it
EP2797942A4 (en) COMPOSITION OF NOVEL CARBOHYDRATE MEDICINE FOR THE TREATMENT OF HUMAN DISEASES
IN2015DN00450A (https=)
IL234701B (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
IL236664B (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
JP2015530399A5 (https=)
WO2014012094A3 (en) Tetracycline compounds for treating neurodegenerative disorders